American Society of Hematology

2017 Friday Scientific Workshops

Applications for Friday Scientific Workshops at the 2018 ASH Annual Meeting are now open. Learn more.

The Friday Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

For questions about any of the Friday Scientific Workshops, please contact ASH Scientific Programs Specialist Nneka Iwuchukwu at niwuchukwu@hematology.org.

FSW Image 1

Hematology & Aging: Highlighting Novel Science and Promoting a Research Agenda

This workshop will discuss scientific findings related to aging and hematologic disorders, spanning topics from bench to bedside.

Co-Chairs: Rebecca L. Olin, MD, and Tanya M. Wildes, MD, MSCI

FSW Image 2

Hemoglobin Concentrations for Defining Anemia in Individuals and Populations

This workshop will present key scientific data underlying the process of evaluating current WHO thresholds for defining anemia.

Chair: Sant-Rayn Pasricha, MD, PhD

Inherited Hematopoietic Malignancies

This workshop will discuss the scientific advances in understanding the pathogenesis of cancer development in individuals and families with germline mutations and predisposition to bone marrow derived malignancies.

Chair: Lucy Godley, MD, PhD

Integrative Clinical & Molecular Epidemiology of Hematologic Malignancies

This workshop will highlight aspects of clinical and molecular epidemiology with emphasis on non-malignant precursor disease states and the factors associated with transformation of hematologic malignancy.

Co-Chairs: Wendy Cozen, DO, and James M. Foran, MD

Myeloid Development

This workshop will examine the latest scientific findings in myeloid biology, with a focus on hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, and epigenetic effects.

Co-Chairs: Leonard Zon, MD, and Ross L. Levine, MD

Tumor Immune Interactions in Lymphoid Malignancies

This workshop will highlight basic and translational immune research as well as potential likely to be important in treating lymphoid malignancies.

Co-Chairs: Stephen M. Ansell, MD, PhD, and Ronald Levy, MD

Friday Scientific Workshop on Hematology and Aging: Highlighting Novel Science and Promoting a Research Agenda

Friday, December 8, 2017, 1:00 p.m. - 5:40 p.m.
Georgia World Congress Center, Bldg B- Lvl 2- B216-B217

Please click here to review this session

As the number of older patients with hematologic disorders dramatically increases, an enhanced focus on aging is needed. The Workshop on Hematology and Aging will discuss scientific findings related to aging and hematologic disorders, and will span topics from bench to bedside. This interactive workshop is not disease specific but will consider common themes related to aging in multiple settings. The workshop will include research on stem cells and aging, implications of aging on immune function (immunosenescence, immune reconstitution), thrombosis and aging, and correlates of frailty in hematology. Topics will cut across basic and clinical areas, as well as across disease types and clinical fields. Emphasis will be made on biologic mechanisms and implications for translation of clinical observations to pre-clinical models. The target audience for this workshop is laboratory-based investigators and clinical researchers with an interest in aging and hematology. The expansive content, thematic focus, and interactive format will also appeal to a broader audience including students and trainees.

Workshop Objectives:

  1. Provide a forum within ASH for presentation of novel research related to the biology of aging and hematologic disorders.
  2. Promote discussion of a research agenda: what are the highest priority questions and new approaches needed to answer them?
  3. Highlight opportunities for collaboration.

This interactive workshop will feature brief didactic presentations from speakers on key topics followed by a few minutes of Q&A.

Workshop Schedule

1:00 p.m. - 1:05 p.m.

Opening Remarks

Chair:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Co-Chair:

Tanya M. Wildes, MD, MSCI
Washington University School of Medicine
St Louis, MO

1:05 p.m. - 2:05 p.m.

Stem Cells and Aging

Moderator:

Ashley E. Rosko, MD
The Ohio State University
Columbus, OH

Speakers:

Michael Gustave Poulos, PhD
Weill Cornell Medical College
New York, NY
Aging Vascular Endothelium Modulate Hematopoietic Stem Cell Activity

Gerald De Haan, PhD
University of Groningen
Groningen, Netherlands
Molecular Mechanisms That Contribute to Hematopoietic Stem Cell Aging

Laura M. Calvi, MD
University of Rochester School of Medicine and Dentistry
Rochester, NY
Defects in Aging Marrow Macrophages Regulate Hematopoietic Stem Cells

Cynthia E. Dunbar, MD
National Institutes of Health
Bethesda, MD
Creation of a Non-Human Primate Model for Hematopoietic Aging and for Chip

2:05 p.m. - 2:20 p.m.

Panel Discussion/Questions

2:20 p.m. - 3:20 p.m.

Aging, Inflammation and Immune Function

Moderator:

Andrew Artz, MD
University of Chicago
Chicago, IL

Speakers:

Hartmut Geiger, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
Stem Cells Aging and Immunity

Fabienne Lucas, MD PhD
The Ohio State University Wexner Medical Center
Columbus, OH
Transplant as a Model for Accelerated T-Cell Aging

Bindu Kanapuru, MD
U.S. Food and Drug Administration
Vienna, VA
Immunotherapy in Older Adults with Hematological Malignancies

Vu Luan Dang Chi, MD
Free University of Brussels
Brussels, Belgium
Age-Related BACH2 Expression Down-Regulation and Decreased Apoptosis in Major Lymphocyte Subsets in Healthy Donors and B-Chronic Lymphocytic Leukemia Patients.

3:20 p.m. - 3:35 p.m.

Panel Discussion/Questions

3:50 p.m. - 4:35 p.m.

Thrombosis and Aging

Moderator:

Matthew T. Rondina, MD
University of Utah
Salt Lake City, UT

Speakers:

Matthew T. Rondina, MD
George E Wahlen VAMC Geriatric Research and Education Clinical Center
Salt Lake City, UT
Platelet Reprogramming and Thrombosis in Aging

Alisa S. Wolberg, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC
In Vitro and In Vivo Models to Dissect the Pathophysiology of Thrombosis in Aging

Pavel Davizon-Castillo, MD
University of Colorado - Pediatric Hematology/Oncology/BMT
Aurora, CO
The Megakaryocyte-Platelet Axis and Pro-Thrombotic Functional Responses in a Murine Model of Aging

4:35 p.m. - 4:50 p.m.

Panel Discussion/Questions

4:50 p.m. - 5:20 p.m.

Clinical and Biologic Correlates of Frailty in Hematology

Moderator:

Heidi Klepin, MD
Wake Forest School of Medicine
Winston-Salem, NC

Speakers:

Paul A. Hamlin, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Geriatric Assessment Among Older Adults with Lymphoma

Raul Cordoba, MD, PhD
Fundación Jimenez Díaz
Madrid, Spain
Brief Comprehensive Geriatric Assessment in Older Patients with Hematological Malignancies: The Gah Scale. a Nation-Wide Dissemination Strategy to Implement the Tool in Spain

5:20 p.m. - 5:35 p.m.

Panel Discussion/Questions

5:35 p.m. - 5:40 p.m.

Closing Remarks

Co-Chair:

Tanya M. Wildes, MD, MSCI
Washington University School of Medicine
St Louis, MO

back to top

Friday Scientific Workshop on Hemoglobin Concentrations for Defining Anemia in Individuals and Populations

Friday, December 8, 2017, 1:00 p.m. - 4:45 p.m.
Georgia World Congress Center, Bldg B- Lvl 2- B213-B214

Please click here to review this session. 

Accurate case definition of anemia is critical for clinical diagnosis, to enable patient care, and for understanding the epidemiology of this problem to plan public health interventions. Appropriate definitions of anemia are therefore crucial for both clinical and public health medicine. Current hemoglobin thresholds the World Health Organization (WHO) recommends for men, women, young children, and pregnancy were proposed in 1968. However, concerns have been raised about the suitability of the current thresholds. WHO, in collaboration with the US Centers for Disease Control and Prevention (CDC) are reviewing the evidence underlying current thresholds and undertaking a program of research to help ensure these thresholds are appropriate. The hematology community comprise the most important clinical stakeholder group and are the group with technical expertise to support this program. It is therefore crucial that hematologists have an opportunity to be informed about and to provide input into this process. This workshop will present key scientific data underlying the process, and will provide an open forum for hematologists to discuss the data and further research plans. It will also provide a forum for new basic science and epidemiology surrounding anemia at the clinical and population health level to be presented and discussed.

Workshop Objectives:

  1. To outline the rationale and process for review and revision of the WHO hemoglobin thresholds.
  2. To identify and present key data which could provide the evidence that would be needed to define WHO hemoglobin thresholds.
  3. To present key scientific and experimental data which may inform the process by which hemoglobin thresholds should be defined by WHO.
  4. Deliver a highly interactive workshop, with a strong focus on collaboration between the hematology community and the WHO process.
  5. To provide feedback to WHO from the hematology community based on discussions and outcomes of the meeting.

The format of this workshop will comprise an overview of the problem and the topic, followed by a series of didactic presentations accompanied by time for questions and answers. This will include both a series of public health related research presentations focusing on anemia, as well as basic biology/ laboratory based presentations focusing on iron metabolism and erythroid biology as it relates to this question. Both data presented at the WHO meeting held in Geneva and supporting, basic data will be presented. At the conclusion of the presentations, the chairs will summarize the key points presented, and allow further time for more general questions and answers, followed by a final summing up. This workshop is directed at laboratory-based investigators, clinicians, trainee hematologists interested in anemia and individuals interested in the guideline development process at the World Health Organization.

Workshop Schedule

1:00 p.m. - 1:05 p.m.

Opening Remarks

Chair:

Sant-Rayn Pasricha, MD, PhD
Weatherall Institute of Molecular Medicine, University of Oxford
Oxford, United Kingdom

Co-Chair:

Dorine W. Swinkels, MD, PhD
Radboud University Medical Centre
Nijmegen, Netherlands

1:05 p.m. - 2:55 p.m.

Hemoglobin Thresholds and Population Health

Moderator:

Dorine W. Swinkels, MD, PhD
Radboud University Medical Centre
Nijmegen, Netherlands

Speakers:

Sant-Rayn Pasricha, MD, PhD
Weatherall Institute of Molecular Medicine, University of Oxford
Oxford, United Kingdom
Overview of the World Health Organization Hemoglobin Thresholds Project

Robert T. Means Jr., MD
East Tennessee State University
Johnson City, TN
Current Hemoglobin Cutoffs: How Did We Get Here?

Elizabeta Nemeth, PhD
University of California, Los Angeles
Los Angeles, CA
Effects of Inflammation on Hemoglobin Concentrations - Mechanisms and Clinical Effects

Melissa Fox Young, PhD
Emory University
Atlanta, GA
Evidence for Hemoglobin Thresholds and Functional Outcomes in Young Children and in Pregnancy

Parmi Suchdev, MD, MPH
Emory University
Atlanta, GA
The Epidemiology and Determinants of Anemia in Low Income Countries

Max Gassmann, DVM
University of Zurich
Zurich, Switzerland
Effects of Hypoxia, Altitude and Smoking on Hemoglobin Concentrations

3:10 p.m. - 4:30 p.m.

Hemoglobin Thresholds and Clinical Medicine

Moderator:

Sant-Rayn Pasricha, MD, PhD
Weatherall Institute of Molecular Medicine, University of Oxford
Oxford, United Kingdom

Speakers:

Domenico Girelli, MD, PhD
University of Verona
Verona, Italy
Hemoglobin Thresholds in the Elderly

Erica Wood, MD
Monash University
Melbourne, Australia
Hemoglobin Concentrations and Transfusion Thresholds

Dorine W. Swinkels, MD, PhD
Radboud University Medical Centre
Nijmegen, Netherlands
Laboratory Measurement of Hemoglobin in Clinical Laboratory Practice and the Field

Stefano Rivella, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
Erythroid Genetics and Hemoglobin Concentrations

4:30 p.m. - 4:40 p.m.

Conclusions and Study Needs

Panelists:

Maria Nieves Garcia-Casal
World Health Organization
Genève, Switzerland

Andrea Sharma, PhD, MPH
Centers for Disease Control and Prevention
Atlanta, GA

4:40 p.m. - 4:45 p.m.

Closing Remarks

Chair:

Sant-Rayn Pasricha, MD, PhD
Weatherall Institute of Molecular Medicine, University of Oxford
Oxford, United Kingdom

Co-Chair:

Dorine W. Swinkels, MD, PhD
Radboud University Medical Centre
Nijmegen, Netherlands

back to top

Friday Scientific Workshop on Inherited Hematopoietic Malignancies

Friday, December 8, 2017, 1:00 p.m. - 6:00 p.m.
Georgia World Congress Center, Bldg B- Lvl 2- B211-B212

Please click here to review this session.

Genetic contribution to the development of hematopoietic malignancies and the need for understanding predisposition genes, mutation distributions, and clinical phenotypes continues to be of great interest to the hematology community. The Workshop on Inherited Hematopoietic Malignancies will discuss the scientific advances in understanding the pathogenesis of cancer development in individuals and families with germline mutations and predisposition to bone marrow derived malignancies. The workshop will concentrate on known familial syndromes, including germline RUNX1, ETV6, ANKRD26, DDX41, GATA2, CEBPA, and other mutations that predispose to myeloid malignancies. The workshop will also discuss other well described syndromes such as Li-Fraumeni germline TP53 mutations as well as inherited lymphoid malignancies and pedigrees of high interest that have no known genetic predisposition alleles identified. The workshop will be conducted with an interactive format, encouraging input from audience members. Although the main focus of the workshop will be scientific in nature, discussions will also emphasize the clinical identification of individuals and families. This workshop will appeal to clinicians who have an interest or are studying inherited hematopoietic malignancies.

Workshop Objectives:

  1. To discuss on-going research efforts in specific predisposition syndromes.
  2. To strengthen existing and to develop new collaborations in these diseases.
  3. To discuss interesting pedigrees that have tested negative for all known predisposition alleles to date and to combine pedigrees with similar phenotypes.
  4. To inform ASH members who are clinicians about these predisposition syndromes and provide contacts to facilitate testing/expand research.
  5. To discuss sequencing approaches, limitations, timing, and circumstances for variant evaluation.

This workshop is designed to be very interactive to allow for maximal interaction and collaborations based on similar interests. The format will include didactic sessions with opportunities for Q&A.

Workshop Schedule

1:00 p.m. - 1:10 p.m.

Opening Remarks

Chair:

Lucy Godley, MD,PhD
University of Chicago
Chicago, IL

1:10 p.m. - 1:55 p.m.

Identification of Germline Syndromes

Moderators:

Jun J. Yang, PhD
St. Jude Children's Res. Hosp.
Memphis, TN

Alison A. Bertuch, MD, PhD
Texas Children's Hospital
Houston, TX

Speakers:

Blanche P. Alter, MD, MPH
National Institutes of Health National Cancer Institute
Rockville, MD
MDS in Inherited Bone Marrow Failure Syndromes

Christian P. Kratz, MD
Hannover Medical School
Hannover, Germany
Children with Cancer Predisposition Syndromes in Germany: Activities of the Society of Pediatric Oncology and Hematology

Christopher N. Hahn, PhD
SA Pathology
Adelaide, SA, Australia
Surprises in "Solving" Families with Predisposition to Hematopoietic Malignancy

Courtney D. DiNardo, MD,MSc
UT MD Anderson Cancer Center
Houston, TX
Incorporating MDS/AML Molecular Profiling at Diagnosis into the Evaluation of Hereditary Leukemia Predispositions

Sarah Bannon, MS, CGC
The University of Texas MD Anderson Cancer Center
Houston, TX
Unique Role of Genetic Counselors in Hematologic Malignancies

1:55 p.m. - 2:40 p.m.

Novel Aspects of Known Predisposition Syndrome

Moderators:

Hamish S. Scott, PhD, FFSc (RCPA), FAHMS
SA Pathology & University of South Australia
Adelaide, Australia

Marcin W. Wlodarski, MD, PhD
University of Freiburg
Freiburg, Germany

Speakers:

Emilia J. Kozyra, MSc
University Childrens Hospital Freiburg
Freiburg, Germany
Synonymous Exonic Substitutions Constitute a New Class of Mutations Causing GATA2 Deficiency

Hideki Makishima, MD, PhD
Kyoto University
Kyoto, Japan
Comprehensive Evaluation of DDX41 Risk Alleles in Non-Familial Cases, General Individuals, and Donor-Derived Leukemias

Jorge Di Paola, MD
University of Colorado School of Medicine
Englewood, CO
A Novel Murine Model of an ETV6 Germline Mutation

Bianca Tesi, MD
Karolinska Institute
Stockholm, Sweden
Clinical and Molecular Features of Patients with SAMD9L-Germline Mutations

Gary M. Kupfer, MD
Yale School of Medicine
New Haven, CT
Fanconi/BRCA Recombination Activity in Vitro and in Cells and Enhancement of Cancer Therapy

2:40 p.m. - 3:25 p.m.

Emerging New Syndromes

Moderators:

Mary Y. Armanios, MD
Johns Hopkins University
Baltimore, MD

Prapti A. Patel, MD
University of Texas Southwestern
Dallas, TX

Speakers:

Victor Pastor Loyola, MSc
Freiburg University Hospital
Freiburg, Germany
Familial MDS and Transient Monosomy 7 as a Sole Clinical Manifestation of SAMD9L-disease

Ian Majewski, PhD
The Walter and Eliza Hall Institute of Medical Research
Parkville, Victoria, Australia
A New Cancer Predisposition Syndrome with a Common Path to AML

ANA Rio-Machin, PhD, BS
Queen Mary University of London
London, United Kingdom
Challenge of Identifying Novel Predisposing Variants in Familial MDS/AML

Tim Ripperger, MD, PhD
Hannover Medical School
Hannover, Germany
Mecom/EVI1: A Novel Candidate Gene for Hereditary Hematological Malignancies

3:40 p.m. - 4:25 p.m.

Effects of Combinations of Germline Variants Including Penetrance/Molecular Progression

Moderators:

Elizabeth A. Griffiths, MD
Roswell Park Cancer Institute
Buffalo, NY

Carolyn Jane Owen, MD, FRCPC
Foothills Hospital & Tom Baker Cancer Center
Calgary, AB, Canada

Speakers:

Inga Hofmann, MD
University of Wisconsin
Madison, WI
Predisposition to Pediatric Myelofibrosis and Thrombocytopenia

Csaba Bödör, PhD
Semmelweis University
Budapest, Hungary
JAK/STAT Pathway Aberrations in RUNX1 Mutated Patients

Thomas Laframboise, PhD
Case Western Reserve University
Cleveland, OH
Germline Contributors to Myeloid Malignancy Susceptibility: Integrating Clues from the Malignant Genome

Kim E. Nichols, MD
St. Jude Children's Research Hospital
Memphis, TN
Hiding Beneath the Surface: Unbiased Screening of the Germline Identifies Unsuspected Cancer Predispositions in Pediatric Leukemia Patients

4:25 p.m. - 5:10 p.m.

Reporting of Families and Variant Interpretation

Moderators:

Marshall Horwitz, MD
University of Washington
Seattle, WA

Michael Francis Walsh, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Speakers:

Matthew P. Collin, MD, PhD
Newcastle University
Newcastle Upon Tyne, United Kingdom
Immune Defects Associated with GATA2 Mutation

Karin Wadt, MD, PhD
Rigshospitalet Copenhagen
Copenhagen, Denmark
Reporting in Scandanavian Populations

Isabelle Plo, PhD
Gustave Roussy
Villejuif, France
Predisposition to Familial MPNs

Jeffery M. Klco, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN
SAMD9/9L Germline Mutations in Familial MDS/AML

5:10 p.m. - 5:55 p.m.

Point-Counter Point: Prophylactic Transplantation for Leukemia Predisposition Syndromes

Moderators:

Christopher C. Porter, MD
Emory University
Atlanta, GA

Luke Maese, DO
University of Utah/Primary Children's Hospital
Salt Lake City, UT

Panelists:

Kayla Hamilton, MS, CGC
St. Jude Children's Research Hospital
Memphis, TN

Luke Maese, DO
Priman Children's Medical Center
Salt Lake City, UT

Michael A. Pulsipher, MD
Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine
Los Angeles, CA

Jonathan M Marron, MD,MPH
Children's Hospital Boston, Dana-Farber Cancer Institute
Boston, MA

5:55 p.m. - 6:00 p.m.

Closing Remarks

Chair:

Lucy Godley, MD,PhD
University of Chicago
Chicago, IL

back to top

Friday Scientific Workshop on Integrative Clinical & Molecular Epidemiology of Hematologic Malignancies

Friday, December 8, 2017, 1:00 p.m. - 6:00 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B404

Please click here to review this session.

Integrative epidemiology addresses fundamental questions regarding the development and prevention of hematologic malignancies in populations. Epidemiologic research is of increasing importance in the era of large scale genomics and databases, where large numbers of patients must be accumulated to study subtle individual effects that translate into large population effects. Population studies can identify risk predictors for disease, progression and outcome, which may have a substantial impact on clinical care. In addition, each of the major hematologic malignancies [leukemia, lymphoma, and myeloma] can arise from precursor states, although the relative contribution of clonal hematopoiesis, monoclonal B-lymphocytosis, and monoclonal gammopathy of undetermined significance (MGUS) to the disease process and the host, clinical or molecular co-factors involved in transformation remains uncertain. The Workshop on Integrative Clinical & Molecular Epidemiology of Hematologic Malignancies will provide a unique forum for discussions around integrative clinical and molecular epidemiology of hematologic malignancies with emphasis on non-malignant precursor disease states and the factors associated with transformation to hematologic malignancy. This workshop is directed at national and international leaders interested in basic and clinical epidemiology as well as cancer prevention. The workshop will also appeal to trainees in public health and preventive medicine; clinical and translational epidemiology; and associated hematology outcomes research.

Workshop Objectives

  1. To provide a unique forum at the ASH Annual Meeting to discuss and present advances in the field of integrative clinical and molecular epidemiology of hematologic malignancies with a particular focus on non-malignant precursor disease states and the factors associated with transformation to hematologic malignancy for the development of targeted screening and prevention;
  2. To extend novel observations generated from epidemiology studies to translational studies with direct clinical relevance.
  3. To develop a roadmap and future directions that advance the study of epidemiology particularly including prevention strategies for lymphoid and myeloid malignancy.
  4. To establish a forum that enhances current collaborations, develops new collaborations, and provides opportunities for career development for trainees and junior investigators in epidemiology of hematologic malignancy.

The format of this workshop will include didactic sessions and focused panel discussions.

Workshop Schedule

1:00 p.m. - 1:05 p.m.

Opening Remarks

Chair:

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA

Co-Chair:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

1:05 p.m. - 2:25 p.m.

New Findings From Population Studies of B-Cell Lymphoma and Leukemia

Moderators:

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA

Speakers:

Jeffrey M. Switchenko, PhD, MS
Emory University
Atlanta, GA
Geospatial Exposure to Benzene and Lymphoma Risk in Georgia

Susan L. Slager, PhD
Mayo Clinic
Rochester, MN
Genetic Risk Factors for CLL Precursors in Families

Marta Epeldegui, PhD
University of California at Los Angeles, David Geffen School of Medicine
Los Angeles, CA
A Prospective Study of Serum Microbial Translocation and Inflammation Associated Biomarkers and Risk of AIDS-Related Non-Hodgkin Lymphoma

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA
Immunological Aging in Adolescent/Young Adult Hodgkin Lymphoma Survivors Compared to Their Unaffected Twins

Maria S. Oliveira
Instituto Nacional de Câncer
Rio de Janeiro, Brazil
Early-Age Leukemias in Brazil

Smita Bhatia, MD, MPH
University of Alabama at Birmingham
Birmingham, AL
Adherence to Oral Chemotherapy in Children with ALL: Contribution to Disparities in Outcomes

2:25 p.m. - 2:35 p.m.

Next Steps for B-cell Neoplasms Epidemiology: Towards Translation

Panelists:

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Jeffrey M. Switchenko, PhD, MS
Emory University
Atlanta, GA

Smita Bhatia, MD, MPH
University of Alabama at Birmingham
Birmingham, AL

Marta Epeldegui, PhD
University of California at Los Angeles, David Geffen School of Medicine
Los Angeles, CA

Susan L. Slager, PhD
Mayo Clinic
Rochester, MN

Maria S. Oliveira
Instituto Nacional de Câncer
Rio de Janeiro, Brazil

2:35 p.m. - 3:35 p.m.

Epidemiology of Myeloid Malignancy: Precursor States and Risk Factor Update

Moderators:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Lindsay M. Morton, PhD
National Cancer Institute, National Institutes of Health
Bethesda, MD

Speakers:

Nancy K. Gillis, PharmD
Moffitt Cancer Center
Tampa, FL
Pre-Existing Chip and Risk of Therapy-Related Myeloid Neoplasms

Koichi Takahashi, MD
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Next Steps with Chip and Myeloid Neoplasms – Informing Risk & Prevention

Sudipto Mukherjee, MD, PhD, MPH
Cleveland Clinic
Cleveland, OH
Risk Prediction for MDS: Novel Clinical and Molecular Risk Factors and Development of Prevention Strategies

Lene Sofie Granfeldt Oestgaard, MD,PhD
Aarhus University Hospital
DK-8000 Aarhus C, Denmark
Clinical Epidemiology & Impact of Therapy-Related AML

3:35 p.m. - 3:45 p.m.

Next Steps for Myeloid Neoplasm Clinical & Molecular Epidemiology: Towards Translation

Panelists:

Lindsay M. Morton, PhD
National Cancer Institute, NIH, DHHS
Bethesda, MD

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

3:45 p.m. - 5:05 p.m.

Understanding the Risk Pathway of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma: Contributions From Epidemiology

Moderators:

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA

Ola Landgren, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Speakers:

Catherine R. Marinac, PhD
Dana-Farber Cancer Institute
Boston, MA
Elucidating the Association of Obesity with Multiple Myeloma Risk: Prospective Studies of Body Size throughout Life and Weight Stability

Sigurður Yngvi Kristinsson, MD, PhD
University of Iceland
Reykjavik, Iceland
iStopMM - A Nationwide Screening Study of MGUS

Niels Weinhold, PhD
University of Arkansas For Medical Sciences
Little Rock, AR
Functional Follow-up of Potential Risk Variants

Elizabeth E Brown, PhD, MPH
University of Alabama at Birmingham
Birmingham, AL
Differential DNA Methylation Consistent with Progression of Multiple Myeloma

Mark A. Fiala, MSW
Washington University School of Medicine
Saint Louis, MO
Inequalities in Treatment and Outcomes in Multiple Myeloma

Kenneth R. Carson, MD, PhD
Washington University in St. Louis
Saint Louis, MO
Can We Move Towards Prevention in Multiple Myeloma?

5:05 p.m. - 5:45 p.m.

T-and NK-cell Lymphoma/Leukemia: Challenges and Opportunities for Epidemiologic Research

Moderators:

Amanda Termuhlen
Children’s Hospital Los Angeles
Los Angeles, CA

Sophia S. Wang, PhD
City of Hope
Duarte, CA

Speakers:

Amanda Termuhlen
Children’s Hospital Los Angeles
Los Angeles, CA
Review of Epidemiology and Risk Factors for Pediatric T-Cell Lymphoma/Leukemia

Sophia S. Wang, PhD
City of Hope
Duarte, CA
Review of Epidemiology of Risk Factors for Adult Peripheral T-Cell Lymphoma/Leukemia

Fredrik Ellin, MD, MSc
Lund University
Lund, Sweden
T-Cell Lymphomas on a Nation-Wide Level - Experiences from the Population-Based Swedish Lymphoma Registry

5:45 p.m. - 5:55 p.m.

How to Build an Epidemiological Research Community in T-cell Lymphoma/Leukemia

Panelists:

Sophia S. Wang, PhD
City of Hope
Duarte, CA

Amanda Termuhlen
Children’s Hospital Los Angeles
Los Angeles, CA

Fredrik Ellin, MD, MSc
Kalmar County Hospital
Kalmar, Sweden

5:55 p.m. - 6:00 p.m.

Closing Remarks

Chair:

Wendy Cozen, DO,MPH
Univ. of Southern California Norris Cancer Ctr.
Los Angeles, CA

Co-Chair:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

back to top

Friday Scientific Workshop on Myeloid Development

Friday, December 8, 2017, 1:00 p.m. - 5:50 p.m.
Georgia World Congress Center, Bldg A- Lvl 4- Marcus Aud.

Please click here to review this session.

The Workshop on Myeloid Development will examine the latest scientific findings in myeloid biology in a highly interactive environment that permits exchange of ideas among investigators. The workshop will focus on topics such as; hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology. Each session leader will briefly summarize the current questions facing the field and then lead discussions on how best to answer those questions. New findings or novel techniques that provide insight into these questions will be an essential part of all discussions. The research presented at this workshop will also focus on the use of molecular biology and biochemistry tools, as well as animal models to address the core topics; it will not include any purely clinical, epidemiologic, or population based approaches. This workshop is directed at laboratory-based investigators, but the broad-ranging content and highly interactive format is suitable for clinically oriented investigators and is particularly appealing to young investigators, giving them the opportunity to interact directly with experts in the field.

Workshop Objectives:

  1. Discuss the latest scientific developments in hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors and epigenetic effects, and other topics related to myeloid biology.
  2. Have interactive presentations by world-class scientists.
  3. Provide young investigators opportunities to interact with world-renowned experts in the field.

The format of this workshop will include brief didactic sessions followed by a couple minutes of Q&A.

Workshop Schedule

1:00 p.m. - 1:05 p.m.

Opening Remarks

Chair:

Leonard Zon, MD
Harvard University
Boston, MA

Co-Chair:

Ross L. Levine, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

1:05 p.m. - 1:50 p.m.

Stem Cells

Moderator:

Patricia Ernst, PhD
University of Colorado Denver Anschutz Medical Campus
Aurora, CO

Speakers:

Marie-Dominique Filippi, PhD, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
Mitochondrial Morphology Controls Hematopoietic Stem Cell Self-Renewal and Confers Them Divisional Memory

Kira Gritsman, MD, PhD
Albert Einstein College of Medicine
Bronx, NY
The PI3 Kinases Alpha and Delta Are Required for the Loss of Hematopoietic Stem Cell Quiescence during Stress

Wei Tong, PhD
Children's Hospital of Philadelphia
Philadelphia, PA
Lnk/Sh2b3 Deficiency Restores Hematopoietic Stem Cell Function and Genome Integrity in Fanconi Anemia

Grant A. Challen, PhD
Washington University School of Medicine
St Louis, MO
Kdm6b Is Required for Hematopoietic Stem Cell Self-Renewal Under Proliferative Stress

1:50 p.m. - 2:35 p.m.

Signaling and Developmental Hematopoiesis

Moderators:

David Traver, PhD
University of California, San Diego
La Jolla, CA

Claudia Lengerke, MD
University Hospital Basel
Basel, Switzerland

Speakers:

Britta Will, PhD
Albert Einstein College of Medicine
Bronx, NY
The Labile Iron Pool As a Rheostat for Hematopoietic Stem Cell Function

Andreas Trumpp, Prof, PhD
Deutsches Krebsforschungszentrum (DKFZ)
Heidelberg, Germany
BCAT1 Restricts a-Ketoglutarate Levels in AML Stem Cells Leading to DNA Hypermethylation Mimicking Idhmut-AML

Jian Xu, PhD
The University of Texas Southwestern Medical Center
Dallas, TX
Interplay between Epigenetics and Metabolism in Hematopoiesis and Leukemia

Toshio Kitamura, MD, PhD
The Institute of Medical Science, The University of Tokyo
Tokyo, Japan
Characterization of Hematopoietic Stem Cells and Progenitors Using a Novel Mouse Expressing a G0 Marker

2:35 p.m. - 3:25 p.m.

New Investigators

Moderator:

Nancy E. Speck, PhD
University of Pennsylvania
Philadelphia, PA

Speakers:

Siddhartha Jaiswal, MD, PhD
Brigham and Women's Hospital
Palo Alto, CA
Clonal Hematopoiesis in Human Aging and Disease

Robert S. Welner, PhD
University of Alabama at Birmingham
Birmingham, AL
Transcriptional Hierarchy within the Bone Marrow Niche

Rebekka K. Schneider, MD,PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Megakaryocyte-Mediated Activation of the Transcription Factor Gli1 in Fibrosis-Driving Cells in Myelofibrosis

Vijay G. Sankaran, MD
Boston Children's Hospital
Boston, MA
Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis

3:25 p.m. - 3:35 p.m.

NHLBI Presentation

Update on NHLBI Programs in the Friday session - Scientific Workshop on Myeloid Development

Moderator:

John W. Thomas, PhD
National Heart, Lung, and Blood Institute; National Institutes of Health Division of Blood Diseases & Resources
Bethesda, MD

3:35 p.m. - 3:45 p.m.

NIDDK Presentation

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) supports hematology research, one of the programs in the Division of Kidney, Urologic and Hematologic Diseases (KUH). Many significant and notable advances in hematology have been made using support from NIDDK over the past 67 years (since 1950). Dr. Terry Rogers Bishop will discuss current funding objectives and opportunities.

Moderator:

Terry Rogers Bishop, PhD
National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health
Bethesda, MD

4:15 p.m. - 5:00 p.m.

Transcription Factors/Epigenetics

Moderator:

Ulrich G. Steidl, MD, PhD
Albert Einstein College of Medicine
Bronx, NY

Speakers:

Omar Abdel-Wahab, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Identifying Novel Therapeutic Vulnerabilities in Spliceosomal Mutant Leukemias

Megan E. McNerney, MD, PhD
University of Chicago
Chicago, IL
The 7q Tumor Suppressor, CUX1, Inhibits MDS/MPN in Mice

Lucio H. Castilla, PhD
University of Massachusetts Medical School
Worcester, MA
Role of Cbfbsmmhc / RUNX1 in Maintaining MYC Levels By Modulating Chromatin Dynamics in AML

Shai Izraeli, MD
Tel Aviv University
Modiin, Israel
T/Myeloid Biphenotypic Leukemia Caused By the Fusion Translocation ETV6-NCOA2 (TEL-TIF2)

5:00 p.m. - 5:45 p.m.

Myeloid Malignancies

Moderator:

Benjamin L. Ebert, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA

Speakers:

Chris Vakoc, MD, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
Domain-Focused CRISPR Dropout Screens in AML

Yana Pikman, MD
Dana Farber Cancer Institute
Boston, MA
New Therapeutic Targets in AML

Jun Lu, PhD
Yale School of Medicine
New Haven, CT
A Non-Cell-Intrinsic Tumor-Promoting Function of Tet2 in Myeloid Cells

Takahiro Maeda, MD,PhD
Kyushu University Hospital
Fukuoka, Japan
Genome-Wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway

5:45 p.m. - 5:50 p.m.

Closing Remarks

Chair:

Leonard Zon, MD
Harvard University
Boston, MA

Co-Chair:

Ross L. Levine, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

back to top

Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies

Friday, December 8, 2017, 1:00 p.m. - 5:40 p.m.
Georgia World Congress Center, Bldg B- Lvl 3- B312-B314

Please click here to review this session.

The area of immunotherapy in lymphoid malignancies has exploded in recent years. Multiple new immune therapies are in development in lymphoproliferative diseases, and this exciting progress has been due to an increased understanding of the tumor microenvironment and tumor-immune interactions in these diseases. This proliferation of scientific knowledge has led to multiple potential new treatments including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes and macrophages, as well as new approaches inhibiting immune receptors and cytokine signaling. The Workshop on Tumor Immune Interactions in Lymphoid Malignancies is directed at scientists, researchers, industry partners and clinicians interested in immune approaches for the management of lymphoid malignancies.

Workshop Objectives:

  1. Highlight novel basic science and translational immune research in lymphoid malignancies that are likely to translate in the near future to clinically relevant therapies, biomarkers, or correlative science.
  2. Highlight potential future therapies or therapeutic targets that are likely to be important in lymphoid malignancies.
  3. To have scientists, translational researchers, and clinicians “hear it here first” when it comes to the next big thing in the management of lymphoid diseases.

The format of this workshop will be different from sessions in the annual ASH meeting in that it will be strictly immune focused, highly interactive and somewhat speculative (though based on science), with a strong focus on future translation to the clinic.

Workshop Schedule

1:00 p.m. - 1:05 p.m.

Opening Remarks

Chair:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Co-Chair:

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA

1:05 p.m. - 2:05 p.m.

New Immune Monitoring Methods

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA

Speakers:

Hanlee Ji, MD
Stanford University
Stanford, CA
Methods and Results from Single Cell Analysis of Tumor Microenvironment

Michael Angelo, MD, PhD
Stanford University
Stanford, CA
In Situ Methods of Analysis of Tumor Microenvironment

2:05 p.m. - 2:35 p.m.

Panel Discussion

2:35 p.m. - 3:35 p.m.

Novel Targets and Delivery Systems

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA

Speakers:

Paul Sondel, MD, PhD
University of Wisconsin
Madison, WI
New Methods of Tumor Vaccination

June Helen Myklebust, PhD
Oslo University Hospital
Oslo, Norway
Tigit, a New Target in the Tumor Microenvironment

3:35 p.m. - 4:05 p.m.

Panel Discussion

4:05 p.m. - 5:05 p.m.

Bispecific Antibodies and CAR T cells

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA

Speakers:

Rajat Bannerji, MD, PhD
Cancer Institute of New Jersey
New Brunswick, NJ
Bispecifics Targeting CD20

Renier J. Brentjens, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
CAR-T Cells: Beyond CD19 (BCMA/CD30/armored CARs)

5:05 p.m. - 5:35 p.m.

Panel Discussion

5:35 p.m. - 5:40 p.m.

Closing Remarks

Chair:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Co-Chair:

Ronald Levy, MD
Stanford University School of Medicine
Stanford, CA

back to top